Telomir Pharmaceuticals, Inc.
TELO
Analytical Summary
Telomir Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
5-Year Financial Trajectory
AnnualBullish Indicators
- No bullish signals detected.
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ | FY 2021 Dec 31, 2021 10-K ↗ |
|---|---|---|---|---|---|
| EPS Growth YoY (%) |
41.1%
Excellent
↑
Excellent
Improving
Year-over-year change in earnings per share
Optimal:
> 10%
|
-16.7%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
-1500.0%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
37.0%
Excellent
↑
Excellent
Improving
Year-over-year change in net income |
-26.5%
Weak
Weak
Year-over-year change in net income |
-1430.4%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
32.1%
Excellent
↑
Excellent
Improving
Year-over-year change in free cash flow |
-21.4%
Weak
Weak
Year-over-year change in free cash flow |
-709.2%
Weak
Weak
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ | FY 2021 Dec 31, 2021 10-K ↗ |
|---|---|---|---|---|---|
| FCF / Net Income (x) |
0.35x
Weak
↓
Weak
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.31x
Weak
↓
Weak
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.30x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.55x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ | FY 2021 Dec 31, 2021 10-K ↗ |
|---|---|---|---|---|---|
| Return on Common Equity (%) (%) |
-176.1%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-1274%)
|
— | — |
91.1%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+508%)
|
— |
Secondary lens
Benchmark Lens
Compare TELO against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare TELO against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for TELO
No bullish signals detected
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How TELO compares to all companies
Peer Comparison
TELO vs similar peers
Compare TELO with peers
Stack TELO against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 6 days ago 5 years · 16 quarters